CoChat
Sign Up
Cited by 9Plant biochemistry and biosynthesisProtein Kinase Regulation and GTPase SignalingEnzyme Structure and Function

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Structural Insight into Geranylgeranyl Diphosphate Synthase (GGDPS) for Cancer Therapy

Open access
Pham, Andrew C., Holstein, Sarah A., Borgstahl, Gloria E.O.·2024·Molecular Cancer Therapeutics
DOI 10.1158/1535-7163.mct-23-0358PMC PMC10762340

Published version of a preprint

Open this paper in CoChat — free accountOpen PDF

Abstract

Geranylgeranyl diphosphate synthase (GGDPS), the source of the isoprenoid donor in protein geranylgeranylation reactions, has become an attractive target for anticancer therapy due to the reliance of cancers on geranylgeranylated proteins. Current GGDPS inhibitor development focuses on optimizing the drug-target enzyme interactions of nitrogen-containing bisphosphonate-based drugs. To advance GGDPS inhibitor development, understanding the enzyme structure, active site, and ligand/product interactions is essential. Here we provide a comprehensive structure-focused review of GGDPS. We reviewed available yeast and human GGDPS structures and then used AlphaFold modeling to complete unsolved structural aspects of these models. We delineate the elements of higher-order structure formation, product-substrate binding, the electrostatic surface, and small-molecule inhibitor binding. With the rise of structure-based drug design, the information provided here will serve as a valuable tool for rationally optimizing inhibitor selectivity and effectiveness.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1535-7163.mct-23-0358

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. The substrate binding sites (IPP and FDP). Residues found within 4 Å of the GGDPS substrates in yeast (cyan) and human (green) are represented as sticks. The human AF 2Q80 and IPP-FDP bound yGGDPS structures were used (PDB: 2E8T). A, The IPP binding site (site 1). hGGDPSAF overlaid on top of the IPP-FDP bound yGGDPS shows amino acid residues within 4 Å of the IPP substrate are highly conserved. Individual residues for yGGDPS IPP binding and the corresponding hGGDPSAF IPP binding sites are shown in the following columns. B, The FDP binding site (site 2). hGGDPSAF overlaid on top of the IPP-FDP bound yGGDPS shows amino acid residues within 4 Å of the FDP substrate are highly conserved. Individual residues for yGGDPS FDP binding and the corresponding hGGDPSAF FDP binding sites are shown in the following columns. Mg2+ ions are represented as magenta spheres with positions taken from the hGGDPSAF structure.
Figure 1. The substrate binding sites (IPP and FDP). Residues found within 4 Å of the GGDPS substrates in yeast (cyan) and human (green) are represented as sticks. The human AF 2Q80 and IPP-FDP bound yGGDPS structures were used (PDB: 2E8T). A, The IPP binding site (site 1). hGGDPSAF overlaid on top of the IPP-FDP bound yGGDPS shows amino acid residues within 4 Å of the IPP substrate are highly conserved. Individual residues for yGGDPS IPP binding and the corresponding hGGDPSAF IPP binding sites are shown in the following columns. B, The FDP binding site (site 2). hGGDPSAF overlaid on top of the IPP-FDP bound yGGDPS shows amino acid residues within 4 Å of the FDP substrate are highly conserved. Individual residues for yGGDPS FDP binding and the corresponding hGGDPSAF FDP binding sites are shown in the following columns. Mg2+ ions are represented as magenta spheres with positions taken from the hGGDPSAF structure.CC BY-NC-ND · PubMed Central
Figure 2. The product-binding sites (GGDP and GGDPi). The GGDP binding site (site 3). Residues found within 4 Å of the GGDPS product in its classical and inhibitory site in yeast (cyan) and human (green) are represented as sticks. The human AF 2Q80 and GGDP bound yGGDPS structures were used (PDB: 2E8V and 2Z4V). A, The classical GGDP binding site (site 3). hGGDPSAF overlaid on top of the classically GGDP bound yGGDPS shows amino acid residues within 4 Å of the GGDP product are highly conserved. Individual residues for yGGDPS classical GGDP binding and the corresponding hGGDPSAF GGDP binding sites are shown in the following columns. B, The GGDP inhibitory (GGDPi) binding site (site 4). hGGDPSAF bound at the inhibitory GGDP site overlaid on top of the inhibitory GGDP bound yGGDPS. 18/24 (75%) of the residues found to be within 4 Å of the GGDPi product in either yGGDPS or hGGDPS were completely conserved suggesting high conservation of product-binding residues. Individual residues for GGDPi yGGDPS and GGDPi hGGDPS binding are shown in the following columns. Mg2+ ions are represented as purple spheres in the yGGDPS structure and as magenta spheres in the hGGDPSAF structure.
Figure 2. The product-binding sites (GGDP and GGDPi). The GGDP binding site (site 3). Residues found within 4 Å of the GGDPS product in its classical and inhibitory site in yeast (cyan) and human (green) are represented as sticks. The human AF 2Q80 and GGDP bound yGGDPS structures were used (PDB: 2E8V and 2Z4V). A, The classical GGDP binding site (site 3). hGGDPSAF overlaid on top of the classically GGDP bound yGGDPS shows amino acid residues within 4 Å of the GGDP product are highly conserved. Individual residues for yGGDPS classical GGDP binding and the corresponding hGGDPSAF GGDP binding sites are shown in the following columns. B, The GGDP inhibitory (GGDPi) binding site (site 4). hGGDPSAF bound at the inhibitory GGDP site overlaid on top of the inhibitory GGDP bound yGGDPS. 18/24 (75%) of the residues found to be within 4 Å of the GGDPi product in either yGGDPS or hGGDPS were completely conserved suggesting high conservation of product-binding residues. Individual residues for GGDPi yGGDPS and GGDPi hGGDPS binding are shown in the following columns. Mg2+ ions are represented as purple spheres in the yGGDPS structure and as magenta spheres in the hGGDPSAF structure.CC BY-NC-ND · PubMed Central
Figure 3. Overlay of published ligand-bound GGDPS structures in the hGGDPSAF active site. A, Overlay of the substrates (IPP and FDP) and product (both GGDP and GGDPi sites). B, Overlay of the yGGDPS structure compounds from Chen / Zhang and colleagues in the hGGDPS active site. PDB codes and color are as follows: 2E91 (cyan), 2E92 (brown), 2E93 (sea foam green), 2E94 (light blue), 2E95 (forest green), 2ZEU (dark gray). Bisphosphonate compounds are labeled on the basis of their numbers used in the text. Zoledronic acid (ZOL) and minodronate (MIN) are also abbreviated in the figure. C, Overlay of the compounds coming from Guo and colleagues. PDB codes and colors: 2Z4W (salmon), 2Z4Y (teal), 2Z4Z (purple), 2Z50 (brick red), 2Z52 (gold), 2Z7I (tan), 2Z78 (magenta). Structures were solved with the yGGDPS enzyme and overlaid onto the hGGDPSAF active site. Bisphosphonate compounds are labeled on the basis of the number and abbreviations used in the text (DGBP). D, Overlay of compounds from solved drug-bound hGGDPS structures. FV0109 is the thienopyrimidine-based bisphosphonate investigated by Lacbay and coworkers (PDB: 6C57, pink). Structures of zoledronate (ZOL) and ibandronate (IBN) were solved by Lisnyansky and colleagues. PDB codes are: 6G31 (cyan), 6R4V (dark blue).
Figure 3. Overlay of published ligand-bound GGDPS structures in the hGGDPSAF active site. A, Overlay of the substrates (IPP and FDP) and product (both GGDP and GGDPi sites). B, Overlay of the yGGDPS structure compounds from Chen / Zhang and colleagues in the hGGDPS active site. PDB codes and color are as follows: 2E91 (cyan), 2E92 (brown), 2E93 (sea foam green), 2E94 (light blue), 2E95 (forest green), 2ZEU (dark gray). Bisphosphonate compounds are labeled on the basis of their numbers used in the text. Zoledronic acid (ZOL) and minodronate (MIN) are also abbreviated in the figure. C, Overlay of the compounds coming from Guo and colleagues. PDB codes and colors: 2Z4W (salmon), 2Z4Y (teal), 2Z4Z (purple), 2Z50 (brick red), 2Z52 (gold), 2Z7I (tan), 2Z78 (magenta). Structures were solved with the yGGDPS enzyme and overlaid onto the hGGDPSAF active site. Bisphosphonate compounds are labeled on the basis of the number and abbreviations used in the text (DGBP). D, Overlay of compounds from solved drug-bound hGGDPS structures. FV0109 is the thienopyrimidine-based bisphosphonate investigated by Lacbay and coworkers (PDB: 6C57, pink). Structures of zoledronate (ZOL) and ibandronate (IBN) were solved by Lisnyansky and colleagues. PDB codes are: 6G31 (cyan), 6R4V (dark blue).CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 85

  1. Zhang, 1996, Protein prenylation: molecular mechanisms and functional consequences, Annu Rev Biochem, 65, 241, 10.1146/annurev.bi.65.070196.001325 · DOI
  2. Takai, 2001, Small GTP-binding proteins, Physiol Rev, 81, 153, 10.1152/physrev.2001.81.1.153 · DOI
  3. Tzeng, 2016, Rab-mediated vesicle trafficking in cancer, J Biomed Sci, 23, 70, 10.1186/s12929-016-0287-7 · DOI
  4. Prieto-Dominguez, 2019, Drugging the small GTPase pathways in cancer treatment: promises and challenges, 255
  5. Wang, 2016, Protein prenylation: unique fats make their mark on biology, Nat Rev Mol Cell Biol, 17, 110, 10.1038/nrm.2015.11 · DOI
  6. Swan, 2021, A requirement of protein geranylgeranylation for chemokine receptor signaling and Th17 cell function in an animal model of multiple sclerosis, Front Immunol, 12, 641188, 10.3389/fimmu.2021.641188 · DOI
  7. Vogt, 1996, Protein geranylgeranylation, not farnesylation, is required for the G1 to S phase transition in mouse fibroblasts, Oncogene, 13, 1991
  8. Kuchay, 2019, GGTase3 is a newly identified geranylgeranyltransferase targeting a ubiquitin ligase, Nat Struct Mol Biol, 26, 628, 10.1038/s41594-019-0249-3 · DOI
  9. Shirakawa, 2020, A SNARE geranylgeranyltransferase essential for the organization of the Golgi apparatus, EMBO J, 39, e104120, 10.15252/embj.2019104120 · DOI
  10. Marchwicka, 2022, Protein prenyltransferases and their inhibitors: structural and functional characterization, Int J Mol Sci, 23, 5424, 10.3390/ijms23105424 · DOI
  11. Taylor, 2003, Structure of mammalian protein geranylgeranyltransferase type-I, EMBO J, 22, 5963, 10.1093/emboj/cdg571 · DOI
  12. Thoma, 2000, Phosphoisoprenoid binding specificity of geranylgeranyltransferase type II, Biochemistry, 39, 12043, 10.1021/bi000835m · DOI
  13. Roth, 2020, Geranylgeranyl generosity: a new prenyl-transferase gives a fat to a SNARE protein, EMBO J, 39, e104744, 10.15252/embj.2020104744 · DOI
  14. Reid, 2004, Crystallographic analysis of CaaX prenyltransferases complexed with substrates defines rules of protein substrate selectivity, J Mol Biol, 343, 417, 10.1016/j.jmb.2004.08.056 · DOI
  15. Muehlebach, 2023, Geranylgeranyl diphosphate synthase: role in human health, disease and potential therapeutic target, Clin Transl Med, 13, e1167, 10.1002/ctm2.1167 · DOI
  16. Shah, 2019, Ras and Rap1: A tale of two GTPases, Semin Cancer Biol, 54, 29, 10.1016/j.semcancer.2018.03.005 · DOI
  17. Crosas-Molist, 2022, Rho GTPase signaling in cancer progression and dissemination, Physiol Rev, 102, 455, 10.1152/physrev.00045.2020 · DOI
  18. Kazanietz, 2017, The Rac GTPase in cancer: from old concepts to new paradigms, Cancer Res, 77, 5445, 10.1158/0008-5472.CAN-17-1456 · DOI
  19. Batool, 2019, A structure-based drug discovery paradigm, Int J Mol Sci, 20, 2783, 10.3390/ijms20112783 · DOI
  20. Aplin, 2022, Evolving experimental techniques for structure-based drug design, J Phys Chem B, 126, 6599, 10.1021/acs.jpcb.2c04344 · DOI
  21. Dudakovic, 2011, Geranylgeranyl diphosphate depletion inhibits breast cancer cell migration, Invest New Drugs, 29, 912, 10.1007/s10637-010-9446-y · DOI
  22. Agabiti, 2016, Molecular mechanisms linking geranylgeranyl diphosphate synthase to cell survival and proliferation, Mol Membr Biol, 33, 1, 10.1080/09687688.2016.1213432 · DOI
  23. Agabiti, 2017, Geranylgeranyl diphosphate synthase inhibition induces apoptosis that is dependent upon GGPP depletion, ERK phosphorylation, and caspase activation, Cell Death Dis, 8, e2678, 10.1038/cddis.2017.101 · DOI
  24. Agabiti, 2019, Regulation of the Notch-ATM-abl axis by geranylgeranyl diphosphate synthase inhibition, Cell Death Dis, 10, 733, 10.1038/s41419-019-1973-7 · DOI
  25. Holstein, 2010, Differential activities of thalidomide and isoprenoid biosynthetic pathway inhibitors in multiple myeloma cells, Leuk Res, 34, 344, 10.1016/j.leukres.2009.06.035 · DOI
  26. Dudakovic, 2008, Inhibition of geranylgeranyl diphosphate synthase induces apoptosis through multiple mechanisms and displays synergy with inhibition of other isoprenoid biosynthetic enzymes, J Pharmacol Exp Ther, 324, 1028, 10.1124/jpet.107.132217 · DOI
  27. Wasko, 2011, Bisphosphonates induce autophagy by depleting geranylgeranyl diphosphate, J Pharmacol Exp Ther, 337, 540, 10.1124/jpet.110.175521 · DOI
  28. Dykstra, 2015, Mechanisms for autophagy modulation by isoprenoid biosynthetic pathway inhibitors in multiple myeloma cells, Oncotarget, 6, 41535, 10.18632/oncotarget.6365 · DOI
  29. Haney, 2023, Evaluation of geranylgeranyl diphosphate synthase inhibition as a novel strategy for the treatment of osteosarcoma and Ewing sarcoma, Drug Dev Res, 84, 62, 10.1002/ddr.22012 · DOI
  30. Ullah, 2016, Protein Geranylgeranyltransferase type 1 as a target in cancer, Curr Cancer Drug Targets, 16, 563, 10.2174/1568009616666151203224603 · DOI
  31. Obeng, 2006, Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells, Blood, 107, 4907, 10.1182/blood-2005-08-3531 · DOI
  32. Holstein, 2011, Isoprenoid biosynthetic pathway inhibition disrupts monoclonal protein secretion and induces the unfolded protein response pathway in multiple myeloma cells, Leuk Res, 35, 551, 10.1016/j.leukres.2010.08.008 · DOI
  33. Born, 2013, Targeting HSP90 and monoclonal protein trafficking modulates the unfolded protein response, chaperone regulation and apoptosis in myeloma cells, Blood Cancer J, 3, e167, 10.1038/bcj.2013.64 · DOI
  34. Haney, 2019, In vivo evaluation of isoprenoid triazole bisphosphonate inhibitors of geranylgeranyl diphosphate synthase: impact of olefin stereochemistry on toxicity and biodistribution, J Pharmacol Exp Ther, 371, 327, 10.1124/jpet.119.258624 · DOI
  35. Haney, 2019, Inhibition of geranylgeranyl diphosphate synthase is a novel therapeutic strategy for pancreatic ductal adenocarcinoma, Oncogene, 38, 5308, 10.1038/s41388-019-0794-6 · DOI
  36. Reilly, 2017, Targeting protein geranylgeranylation slows tumor development in a murine model of prostate cancer metastasis, Cancer Biol Ther, 18, 872, 10.1080/15384047.2016.1219817 · DOI
  37. Reilly, 2015, Targeting geranylgeranylation reduces adrenal gland tumor burden in a murine model of prostate cancer metastasis, Clin Exp Metastasis, 32, 555, 10.1007/s10585-015-9727-0 · DOI
  38. Haney, 2021, In vivo evaluation of combination therapy targeting the isoprenoid biosynthetic pathway, Pharmacol Res, 167, 105528, 10.1016/j.phrs.2021.105528 · DOI
  39. Haney, 2022, Geranylgeranyl diphosphate synthase inhibitor and proteasome inhibitor combination therapy in multiple myeloma, Exp Hematol Oncol, 11, 5, 10.1186/s40164-022-00261-6 · DOI
  40. Lacbay, 2018, Unraveling the prenylation-cancer paradox in multiple myeloma with novel Geranylgeranyl Pyrophosphate Synthase (GGPPS) inhibitors, J Med Chem, 61, 6904, 10.1021/acs.jmedchem.8b00886 · DOI
  41. Wang, 2018, Overexpression of geranylgeranyl diphosphate synthase contributes to tumor metastasis and correlates with poor prognosis of lung adenocarcinoma, J Cell Mol Med, 22, 2177, 10.1111/jcmm.13493 · DOI
  42. Yu, 2014, GGPPS1 predicts the biological character of hepatocellular carcinoma in patients with cirrhosis, BMC Cancer, 14, 248, 10.1186/1471-2407-14-248 · DOI
  43. Sagami, 1992, Studies on geranylgeranyl diphosphate synthase from rat liver: specific inhibition by 3-azageranylgeranyl diphosphate, Arch Biochem Biophys, 297, 314, 10.1016/0003-9861(92)90678-P · DOI
  44. Sagami, 1994, Purification and properties of geranylgeranyl-diphosphate synthase from bovine brain, J Biol Chem, 269, 20561, 10.1016/S0021-9258(17)32030-6 · DOI
  45. Chang, 2006, Crystal structure of type-III geranylgeranyl pyrophosphate synthase from Saccharomyces cerevisiae and the mechanism of product chain length determination, J Biol Chem, 281, 14991, 10.1074/jbc.M512886200 · DOI
  46. Guo, 2007, Bisphosphonates target multiple sites in both cis- and trans-prenyltransferases, Proc Natl Acad Sci USA, 104, 10022, 10.1073/pnas.0702254104 · DOI
  47. Kavanagh, 2006, The crystal structure of human geranylgeranyl pyrophosphate synthase reveals a novel hexameric arrangement and inhibitory product binding, J Biol Chem, 281, 22004, 10.1074/jbc.M602603200 · DOI
  48. Wang, 2016, Structural analyses of short-chain prenyltransferases identify an evolutionarily conserved GFPPS clade in brassicaceae plants, Mol Plant, 9, 195, 10.1016/j.molp.2015.10.010 · DOI
  49. Wallrapp, 2013, Prediction of function for the polyprenyl transferase subgroup in the isoprenoid synthase superfamily, Proc Natl Acad Sci USA, 110, E1196, 10.1073/pnas.1300632110 · DOI
  50. Zhou, 2017, A recruiting protein of geranylgeranyl diphosphate synthase controls metabolic flux toward chlorophyll biosynthesis in rice, Proc Natl Acad Sci USA, 114, 6866, 10.1073/pnas.1705689114 · DOI
  51. Chang, 2010, Structure of a heterotetrameric geranyl pyrophosphate synthase from mint (Mentha piperita) reveals intersubunit regulation, Plant Cell, 22, 454, 10.1105/tpc.109.071738 · DOI
  52. Kim, 2019, Crystal structure of geranylgeranyl pyrophosphate synthase (crtE) from Nonlabens dokdonensis DSW-6, Biochem Biophys Res Commun, 518, 479, 10.1016/j.bbrc.2019.08.071 · DOI
  53. Kuzuguchi, 1999, Human geranylgeranyl diphosphate synthase. cDNA cloning and expression, J Biol Chem, 274, 5888, 10.1074/jbc.274.9.5888 · DOI
  54. Miyagi, 2007, Human geranylgeranyl diphosphate synthase is an octamer in solution, J Biochem, 142, 377, 10.1093/jb/mvm144 · DOI
  55. Lisnyansky, 2019, Metal coordination is crucial for geranylgeranyl diphosphate synthase-bisphosphonate interactions: a crystallographic and computational analysis, Mol Pharmacol, 96, 580, 10.1124/mol.119.117499 · DOI
  56. Waterhouse, 2009, Jalview Version 2–a multiple sequence alignment editor and analysis workbench, Bioinformatics, 25, 1189, 10.1093/bioinformatics/btp033 · DOI
  57. Kavanagh, 2006, The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs, Proc Natl Acad Sci USA, 103, 7829, 10.1073/pnas.0601643103 · DOI
  58. Ramsay, 2017, Assessment of enzyme inhibition: a review with examples from the development of monoamine oxidase and cholinesterase inhibitory drugs, Molecules, 22, 1192, 10.3390/molecules22071192 · DOI
  59. Hopkins, 2002, The druggable genome, Nat Rev Drug Discov, 1, 727, 10.1038/nrd892 · DOI · Paper page
  60. Poulter, 1977, Mechanism of the prenyl-transfer reaction. Studies with (E)- and (Z)-3-trifluoromethyl-2-buten-1-yl pyrophosphate, Biochemistry, 16, 5470, 10.1021/bi00644a012 · DOI
  61. Poulter, 1978, Farnesyl pyrophosphate synthetase. Mechanistic studies of the 1'-4 coupling reaction with 2-fluorogeranyl pyrophosphate, J Biol Chem, 253, 7227, 10.1016/S0021-9258(17)34489-7 · DOI
  62. Szabo, 2002, Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates and diphosphates: a potential route to new bone antiresorption and antiparasitic agents, J Med Chem, 45, 2185, 10.1021/jm010412y · DOI
  63. Lisnyansky, 2018, Reduced activity of geranylgeranyl diphosphate synthase mutant is involved in bisphosphonate-induced atypical fractures, Mol Pharmacol, 94, 1391, 10.1124/mol.118.113670 · DOI
  64. Zhang, 2009, Lipophilic bisphosphonates as dual farnesyl/geranylgeranyl diphosphate synthase inhibitors: an X-ray and NMR investigation, J Am Chem Soc, 131, 5153, 10.1021/ja808285e · DOI
  65. K-M Chen, 2008, Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates: a crystallographic and computational investigation, J Med Chem, 51, 5594, 10.1021/jm800325y · DOI
  66. Martin, 1999, Nitrogen-containing bisphosphonates as carbocation transition state analogs for isoprenoid biosynthesis, Biochem Biophys Res Commun, 263, 754, 10.1006/bbrc.1999.1404 · DOI
  67. Sanders, 2003, 3-D QSAR investigations of the inhibition of Leishmania major farnesyl pyrophosphate synthase by bisphosphonates, J Med Chem, 46, 5171, 10.1021/jm0302344 · DOI
  68. Barney, 2010, Synthesis and biological evaluation of a series of aromatic bisphosphonates, Bioorg Med Chem, 18, 7212, 10.1016/j.bmc.2010.08.036 · DOI
  69. Foust, 2016, A new motif for inhibitors of geranylgeranyl diphosphate synthase, Bioorg Med Chem, 24, 3734, 10.1016/j.bmc.2016.06.019 · DOI
  70. Zhou, 2014, Synthesis of isoprenoid bisphosphonate ethers through C-P bond formations: Potential inhibitors of geranylgeranyl diphosphate synthase, Beilstein J Org Chem, 10, 1645, 10.3762/bjoc.10.171 · DOI
  71. Zhou, 2014, Geranyl and neryl triazole bisphosphonates as inhibitors of geranylgeranyl diphosphate synthase, Bioorg Med Chem, 22, 2791, 10.1016/j.bmc.2014.03.014 · DOI
  72. Zhou, 2013, Triazole-based inhibitors of geranylgeranyltransferase II, Bioorg Med Chem Lett, 23, 764, 10.1016/j.bmcl.2012.11.089 · DOI
  73. Allen, 2017, Olefin Isomers of a triazole bisphosphonate synergistically inhibit geranylgeranyl diphosphate synthase, Mol Pharmacol, 91, 229, 10.1124/mol.116.107326 · DOI
  74. Wills, 2015, Potent triazole bisphosphonate inhibitor of geranylgeranyl diphosphate synthase, ACS Med Chem Lett, 6, 1195, 10.1021/acsmedchemlett.5b00334 · DOI
  75. Wills, 2017, Bishomoisoprenoid triazole bisphosphonates as inhibitors of geranylgeranyl diphosphate synthase, Bioorg Med Chem, 25, 2437, 10.1016/j.bmc.2017.02.066 · DOI
  76. Bhuiyan, 2019, omega-Hydroxy isoprenoid bisphosphonates as linkable GGDPS inhibitors, 126633
  77. Matthiesen, 2018, alpha-Methylation enhances the potency of isoprenoid triazole bisphosphonates as geranylgeranyl diphosphate synthase inhibitors, Bioorg Med Chem, 26, 376, 10.1016/j.bmc.2017.10.023 · DOI
  78. Fairweather, 2021, Impact of alpha-modifications on the activity of triazole bisphosphonates as geranylgeranyl diphosphate synthase inhibitors, Bioorg Med Chem, 44, 116307, 10.1016/j.bmc.2021.116307 · DOI
  79. Rees, 2004, Fragment-based lead discovery, Nat Rev Drug Discov, 3, 660, 10.1038/nrd1467 · DOI
  80. Erlanson, 2012, Introduction to fragment-based drug discovery, Top Curr Chem, 317, 1
  81. Kirsch, 2019, Concepts and core principles of fragment-based drug design, Molecules, 24, 4309, 10.3390/molecules24234309 · DOI
  82. Kim, 2023, Target discovery using deep learning-based molecular docking and predicted protein structures with alphafold for novel antipsychotics, Psychiatry Investig, 20, 504, 10.30773/pi.2022.0343 · DOI
  83. Borkakoti, 2023, AlphaFold2 protein structure prediction: Implications for drug discovery, Curr Opin Struct Biol, 78, 102526, 10.1016/j.sbi.2022.102526 · DOI
  84. Naqvi, 2018, Advancements in docking and molecular dynamics simulations towards ligand-receptor interactions and structure-function relationships, Curr Top Med Chem, 18, 1755, 10.2174/1568026618666181025114157 · DOI
  85. Dove, 1999, Drug screening–beyond the bottleneck, Nat Biotechnol, 17, 859, 10.1038/12845 · DOI

Metadata

Authors
Pham, A. C., Holstein, S. A., & Borgstahl, G. E. O.
Affiliations
University of Nebraska Medical Center (US)
Corresponding author
Borgstahl, Gloria E.O.
ORCID
Venue
Molecular Cancer Therapeutics
Publisher
American Association for Cancer Research (AACR)
Published
2023-09-26
Volume
23
Issue
1
Pages
14-23
ISSN
  • 1535-7163 (ISSN-L)
  • 1538-8514
DOI
10.1158/1535-7163.mct-23-0358
PMC
PMC10762340
OpenAlex
W4387089883
Cited by
9
References
1
Citations by year
2026: 4 · 2025: 4 · 2024: 1
FWCI
0.24
Type
journal article
Language
en
Open access
Licence
Locations
  • Molecular Cancer Therapeutics (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
  • National Cancer Institute (R01CA258621, P30CA036727)
  • U.S. Department of Education (P200A210032)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Plant biochemistry and biosynthesis
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Structural Biology › Enzyme Structure and Function
Keywords
geranylgeranyl diphosphate synthase, protein geranylgeranylation, isoprenoid metabolism, anticancer drug targets, enzyme structure, active site, electrostatic surface, structure-based drug design
MeSH terms
Enzyme Inhibitors, Humans, Neoplasms, Terpenes, Protein Prenylation, Farnesyltranstransferase

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Structural Insight into Geranylgeranyl Diphosphate Synthase (GGDPS) for Cancer Therapy. https://app.cochat.ai/papers/10.1158/1535-7163.mct-23-0358
The paper
Pham, A. C., Holstein, S. A., & Borgstahl, G. E. O. (2024). Structural Insight into Geranylgeranyl Diphosphate Synthase (GGDPS) for Cancer Therapy. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-23-0358